SMis RNA Therapeutics: STORM Therapeutics Announces Publication in Nature on RNA Epigenetics
SMi's 9th RNA Therapeutics
London, United Kingdom, December 06, 2017 --(PR.com)-- Storm Therapeutics is the leading drug discovery company for small molecule therapies modulating RNA epigenetics. They have just announced their publication in Nature which links an RNA-modifying enzyme to acute myeloid leukaemia. Targeting the METTL3 gene has been shown to destroy human and mouse AML cells without harming other healthy cells within the body, opening up new avenues for treating this disease. *http://prn.to/2jxTjVE
Professor Tony Kouzarides, Founder of STORM Therapeutics and joint project leader from the Gurdon Institute, University of Cambridge, commented, "This is an important milestone in the understanding of RNA epigenetics and its links to disease. These findings highlight the importance of RNA modifying enzymes in cancer, and in particular in leukaemia. Our study will inspire pharmaceutical efforts to find drugs that specifically inhibit METTL3 to treat AML."
Network at RNA Therapeutics 2018 to hear from Oliver Rausch, VP Research and Development, Storm Therapeutics. Day 1 | 16:00.
Oliver will examine in detail how Storm Therapeutics has harnessed the power of RNA epigenetics to targeting these potentially life changing RNA modifying enzymes. Explore the modifications and regulation of these RNA molecules and how they can be used to interfere with RNA pathways and mechanisms for the treatment of cancer.
Further information is available at: www.therapeutics-rna.com/prc
SMi presents the 9th Annual Conference:
RNA Therapeutics
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Website: www.therapeutics-rna.com/prc
Sponsored by: ChemGenes | Phion Therapeutics
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Professor Tony Kouzarides, Founder of STORM Therapeutics and joint project leader from the Gurdon Institute, University of Cambridge, commented, "This is an important milestone in the understanding of RNA epigenetics and its links to disease. These findings highlight the importance of RNA modifying enzymes in cancer, and in particular in leukaemia. Our study will inspire pharmaceutical efforts to find drugs that specifically inhibit METTL3 to treat AML."
Network at RNA Therapeutics 2018 to hear from Oliver Rausch, VP Research and Development, Storm Therapeutics. Day 1 | 16:00.
Oliver will examine in detail how Storm Therapeutics has harnessed the power of RNA epigenetics to targeting these potentially life changing RNA modifying enzymes. Explore the modifications and regulation of these RNA molecules and how they can be used to interfere with RNA pathways and mechanisms for the treatment of cancer.
Further information is available at: www.therapeutics-rna.com/prc
SMi presents the 9th Annual Conference:
RNA Therapeutics
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Website: www.therapeutics-rna.com/prc
Sponsored by: ChemGenes | Phion Therapeutics
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Pav Solanki
+44 (0) 20 7827 6048
http://www.therapeutics-rna.com/prc
Pav Solanki
+44 (0) 20 7827 6048
http://www.therapeutics-rna.com/prc
Contact
Categories